Stockscreener 앱 받기
1.61
1.90%
0.03
시장 영업 전:
1.60
-0.01
-0.62%
전일 마감가:
$1.58
열려 있는:
$1.61
하루 거래량:
794.85K
Relative Volume:
0.75
시가총액:
$58.19M
수익:
$300.00K
순이익/손실:
$-24.74M
주가수익비율:
-1.6004
EPS:
-1.006
순현금흐름:
$-19.19M
1주 성능:
-1.23%
1개월 성능:
-18.69%
6개월 성능:
+11.81%
1년 성능:
+64.98%
1일 변동 폭
$1.55
$1.65
1주일 범위
$1.52
$1.70
52주 변동 폭
$0.5562
$3.82
iBio Inc Stock (IBIO) Company Profile
명칭
iBio Inc
전화
302-355-0650
주소
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.61 | 58.19M | 300.00K | -24.74M | -19.19M | -1.006 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Oppenheimer | Outperform |
| 2025-10-17 | 개시 | Leerink Partners | Outperform |
| 2024-05-28 | 개시 | Chardan Capital Markets | Buy |
| 2021-11-29 | 개시 | JMP Securities | Mkt Outperform |
| 2021-01-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-06-26 | 개시 | Alliance Global Partners | Buy |
모두보기
iBio Inc 주식(IBIO)의 최신 뉴스
Top iBio (IBIO) Competitors 2026 - MarketBeat
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
iBio (NASDAQ: IBIO) substitutes SILV Fund after 876,340‑share transfer - Stock Titan
IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia - MSN
IBIO (IBIO) price target increased by 18.73% to 5.47 - MSN
iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600 - Yahoo Finance
10 Best NASDAQ Growth Stocks to Buy and Hold Forever - Insider Monkey
IBIO (iBio Inc.) falls 2.37% today after Q1 2026 EPS lands slightly below consensus estimates.Revenue Guidance - Xã Châu Thành
IBIO (iBio Inc.) reports 77.8 percent year over year Q1 2026 revenue growth, shares edge higher.Growth Acceleration - Cổng thông tin điện tử Tỉnh Sơn La
iBio, Inc. 8-K/A Filing Details: Company Information, Address, and Stock Listing (April 8, 2026) - Minichart
iBio (IBIO) clarifies warrant expirations and advances IBIO-600 Phase 1 trial - Stock Titan
IBIO Stock Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
LifeSci Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Is iBio (IBIO) Stock Stable Now | Price at $2.17, Up 0.23%Aggressive Growth Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update - ADVFN
iBio Inc. (IBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ibio (IBIO) Receives a Buy from Chardan Capital - The Globe and Mail
IBIO: Chardan Capital Maintains 'Buy' Rating with $5.00 Price Ta - GuruFocus
Ibio’s IBIO-600 cleared to enter clinic in Australia for obesity - BioWorld News
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia - Sahm
iBio receives approval to start phase 1 trial of IBIO-600 By Investing.com - Investing.com India
Is iBio (IBIO) Stock Risky Now | Price at $2.21, Down 1.12%Alpha Picks - Cổng thông tin điện tử tỉnh Lào Cai
iBio Receives Regulatory Clearance to Begin Phase 1 Trial of IBIO-600, a Long-Acting Anti-Myostatin Antibody for Obesity, in Australia 1 - Minichart
iBio, Inc. (IBIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
iBio Advances to Clinical Stage With IBIO-600 Trial - TipRanks
iBio, Inc. (IBIO) stock price, news, quote and history - Yahoo Finance UK
IBIO Stock Is Soaring Today After iBio's Muscle-Preserving Drug Receives Approval For Human Trial In Australia - Stocktwits
Regulators clear iBio (NASDAQ: IBIO) to launch first-in-human IBIO-600 trial - Stock Titan
iBio receives approval to start phase 1 trial of IBIO-600 - Investing.com
Street Watch: Is iBio Inc a speculative investment2026 Investor Takeaways & Real-Time Volume Spike Alerts - baoquankhu1.vn
IBIO Technical Analysis | Trend, Signals & Chart Patterns | IBIO INC (NASDAQ:IBIO) - ChartMill
Aug Selloffs: Will iBio Inc benefit from green energy policiesInsider Selling & Real-Time Buy Zone Alerts - baoquankhu1.vn
FRA:0JV0 PB Ratio: 1.01 — 33% Below Median - GuruFocus
IBIO Should I Buy - Intellectia AI
iBio Inc. (0JV0.SG) cash flow - Yahoo Finance UK
Can iBio Inc stock double in the next yearQuarterly Performance Summary & Entry and Exit Point Strategies - baoquankhu1.vn
Insider List - GuruFocus
Insider Buying: Marc Banjak Acquires Additional Shares of iBio I - GuruFocus
iBio Inc (IBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):